In a report released today, Stephen Baxter from Wells Fargo maintained a Buy rating on Elevance Health (ELV – Research Report), with a price ...

Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on Elevance Health (ELV – Research Report). The associated price target ...

Shares of Elevance Health Inc. ELV slipped 1.42% to $405.40 Tuesday, on what proved to be an all-around great trading session ...

Before making this announcement, Elevance Health was easily earning enough to cover the dividend. As a result, a large proportion of what it earned was being reinvested back into the business.

Elevance Health Inc. closed 27.50% below its 52-week high of $567.26, which the company achieved on September 3rd.

Analysts' ratings for Elevance Health (NYSE:ELV) over the last quarter vary from bullish to bearish, as provided by 6 analysts. Summarizing their recent assessments, the table below illustrates ...

Unless the payments are sustainable, the dividend yield doesn't mean too much. Before making this announcement, Elevance Health was easily earning enough to cover the dividend. As a result, a large ...

As you can see from the chart above the percentage of shares that are sold short for Elevance Health has grown since its last report. This does not mean that the stock is going to fall in the near ...

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...